NeuroSense Therapeutics Ltd (NRSN) - Market Cap to Earnings
This daily price chart for NeuroSense Therapeutics (NRSN) with the -2.20 indicator illustrates the trajectory of the biotech firm developing ALS therapy and seeking orphan drug designation for PrimeC. The business relies on patent protection against dumping, where success depends on the efficacy of clinical trials. Despite its Israeli origin and regional risks, the company's humanitarian profile safeguards its intellectual property.
Analytical breakdowns for NeuroSense Therapeutics
- current price and projected stock value:
- market capitalization indicators:
- book value of equity indicators:
- debt obligations and liquidity statistics:
Debt to Capital NeuroSense Therapeutics|NRSN - Long-Term Debt to Equity|Short-Term Debt to Capital Coefficient NeuroSense Therapeutics, Ltd.|NRSN - Company Aggregate Debts|Debts to Book Value NeuroSense Therapeutics Ltd.|NRSN - Company Long-Term Debt|Company Short-Term Indebtedness NeuroSense Therapeutics|Interim Coverage Ratio neurosense-tx.com
- net income and valuation ratios data:
NRSN - Net Profit|Expected Net Profit NeuroSense Therapeutics|NRSN - Price to Earnings Ratio|Future Price to Earnings Multiple NeuroSense Therapeutics, Ltd.|NRSN - Price/Earnings to Growth Multiple|Enterprise Value to Operating Income Before Depreciation Ratio NeuroSense Therapeutics Ltd.|NRSN - Operating profit EBITDA|Earnings per share for the trailing year NeuroSense Therapeutics|NRSN - Net earnings per share (EPS TTM)|Earnings per share growth in annualized terms for the last twelve months neurosense-tx.com|NRSN - Earnings per share growth in current year|Expected earnings per share trend next year NeuroSense Therapeutics
Summary company analysis:NRSN (neurosense-tx.com)
The P/E ratio relates the market value of a share to the net profit per share, determining the payback period for investments based on current earnings rates. For NeuroSense Therapeutics (NRSN), which is developing innovative ALS therapy, this indicator reflects market expectations for future breakthroughs, as clearly illustrated by the company's monthly P/E dynamics through the lens of speculative potential and fundamental risks.
Analysis of competing companies
Price to Earnings Multiple BIIB (biogen.com)|P/E Multiple NBIX|RGC - Market Cap to Earnings|Axsome Therapeutics Inc - Price to Earnings Ratio|P/E Multiple ACADIA Corp ACAD|XENE - Price to Earnings Ratio|Company Value to Net Income VKTX (vikingtherapeutics.com)|Supernus (SUPN) - Price to Earnings Ratio|Market Cap to Earnings Catalyst Pharma (CPRX)|Price to Earnings Ratio Denali Therapeutics Inc|Harmony Corp (HRMY) - Business Payback Period|P/E Multiple BHVN|AMLX - Market Cap to Earnings|Price to Earnings Ratio Trevi Therapeutics, Inc. TRVI|PRAX: Price to Earnings Multiple|AVXL - Price to Earnings Ratio|Business Payback Period CeriBell EEG CBLL|PRTA: P/E Multiple|Market Cap to Earnings Alector (ALEC)|Price to Earnings Ratio ANNX|OMER: Company Value to Net Income|Price to Earnings Ratio NGNE (Neurogene Corp)|Market Price to Net Income Ratio ACIU|P/E Multiple VYGR (Voyager Therapeutics)|Company Value to Net Income NMRA|Scilex - P/E Multiple|Market Cap to Earnings Tevogen Bio Holdings Inc.|alphacognition.com (ACOG) - Price to Earnings Ratio|Cognition Therapeutics Inc. - Company Value to Net Income|IKT (Inhibikase Therapeutics) - P/E Multiple|P/E Multiple cassavasciences.com|Price to Earnings Ratio Assertio Holdings, Inc. (ASRT)|COYA: Market Cap to Net Income|P/E Multiple VTGN (Vistagen)|Ovid Therapeutics Inc (OVID) - Market Cap to Earnings|ABOS: Price to Earnings Ratio|CRVO - P/E Multiple|ATHE (alteritytherapeutics.com) - Price to Earnings Ratio|CLNN: Market Price to Net Income Ratio|PEPG (PepGen Inc) - P/E Multiple|Jupiter Neurosciences, Inc. (JUNS) - Business Payback Period|P/E Multiple RLMD|Price to Earnings Ratio annovisbio.com ANVS|Price to Earnings Ratio Grace Therapeutics GRCE|Business Payback Period Firefly Neuroscience, Inc. (AIFF)|KLTO - Price to Earnings Ratio|RVPH (Reviva Pharmaceuticals, Inc.) - Price to Earnings Multiple|metaviatx.com (MTVA) - Price to Earnings Ratio|neuraxis.com - Company Value to Net Income|Price to Earnings Ratio Helius Medical Technologies, Inc.|Passage Bio Corp (PASG) - Business Payback Period|Price to Earnings Ratio Neuphoria Therapeutics Inc. (NEUP)|Minerva - Price to Earnings Multiple|Price to Earnings Ratio Athira Pharma, Inc. ATHA|ADXN: Price to Earnings Multiple|Alzamend - P/E Multiple|Market Cap to Earnings Cyclerion Therapeutics|PTIX (protagenic.com) - Price to Earnings Ratio|Pasithea Therapeutics Corp. (KTTA) - P/E Multiple|Price to Earnings Ratio Cortigent Inc|ATXI: Company Value to Net Income|Price to Earnings Ratio BrainStorm Cell Therapeutics (BCLI)|CARA - Market Cap to Earnings|Price to Earnings Ratio Chromocell Therapeutics Corporation CHRO|ELYM: Price to Earnings Multiple|Intra-Cellular - P/E Multiple|Market Cap to Earnings longboardpharma.com|MRNS (Marinus Pharmaceuticals, Inc.) - Price to Earnings Ratio|NKGen Biotech Inc (NKGN) - P/E Multiple|Price to Earnings Ratio NeuroBo|SAGE: Company Value to Net Income|Price to Earnings Ratio Synaptogenix, Inc. (SNPX)|TRVN - Market Cap to Earnings|Price to Earnings Ratio Vigil Neuroscience, Inc. VIGL|Business Payback Period anewmeds.com (WENA)|Cerevel - P/E Multiple
